NSABP B-31

NSABP B-31

• 批准号: 7607579
• 负责人: Scott Henry Kurtzman
• 金额: $ 0.08万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607579
• 关键词: Adriamycin PFS; Cardiotoxicity; Chemotherapy-Oncologic Procedure; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; ERBB2 gene; Funding; Grant; Histologic; Institution; National Surgical Adjuvant Breast and Bowel Project; Paclitaxel; Patients; Population; Positive Lymph Node; Protein Overexpression; Proteins; Research; Research Personnel; Resources; Roche brand of trastuzumab; Source; United States National Institutes of Health; malignant breast neoplasm

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of the study are 1) to compare the cardiotoxicity of four cycles of Adriamycin and Cyclophosphamide (AC) followed by four cycles of Taxol, with that of the same chemotherapy regimen plus Herceptin, in patients with operable, histologically node-positive breast cancer which overexpresses the HER2 protein; and 2)to determine whether, in this patient population, four cycles of AC followed by four cycles of Taxol and weekly Herceptin for one year is more effective in prolonging survival than four cycles of AC followed by four cycles of Taxol.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是：1)比较阿霉素和环磷酰胺(AC)4周期，然后4周期紫杉醇，与相同的化疗方案加赫赛汀，对HER2蛋白过度表达的可手术的、组织学阳性的乳腺癌患者的心脏毒性；2)确定在这类患者中，4周期AC，4周期紫杉醇和每周1年的Herceptin是否比4周期AC和4周期紫杉醇更有效地延长生存期。